This is the second time writing about the Neurim v Mylan battle “take two” concerning a divisional patent (EP 3 103 443) granted on 30 June 2021 (but expires 12 August 2022). The first article (Neurim v Mylan: Take Two) covered Neurim’s successful application for an expedited preliminary issue trial. That article also covers (some of) the twists and turns of the original Neurim v Mylan battle on the parent patent.
News
CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.
Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors.
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr Peter Jackson, executive director, Infex Therapeutics, said:
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, and reflects the importance of innovative, entrepreneurial companies to the future economic wellbeing of our country as we seek to recover from the pandemic.
"Diagnostics - More important than ever, but there's still a way to go".
Diagnostics are clearly improving and enabling better clinical decisions to be made, especially in oncology where mutation detection is enabling much more personalised approaches to treatment. There is still a long way to go, but combinations of diagnostics tests and technologies (beyond genomics) are giving a more detailed picture on which to base treatment decisions.
Oxford, UK, Friday 15th October: PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.
This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.
AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.
London, UK, 27 October 2021 – Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”) for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.
Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.
Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.
22nd October 2021 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full service finance company for the life sciences, pharma, biotech, deep tech and new energy sector, has recently expanded its portfolio of book-keeping, tax, and CFO services into the UK market. With the appointment of Charles Richmond as their new Director Accounting UK, the company takes the next step towards becoming a dominant player within the international market.